User profiles for Daniel Pan
Daniel PanDepartment of Respiratory Sciences, University of Leicester Verified email at leicester.ac.uk Cited by 5667 |
[HTML][HTML] The impact of ethnicity on clinical outcomes in COVID-19: a systematic review
Background The relationship between ethnicity and COVID-19 is uncertain. We performed a
systematic review to assess whether ethnicity has been reported in patients with COVID-19 …
systematic review to assess whether ethnicity has been reported in patients with COVID-19 …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
…, DR Owens, M Pacurar, A Palfreeman, D Pan… - The Lancet, 2021 - thelancet.com
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
Ethnicity and COVID-19: an urgent public health research priority
As the coronavirus disease 2019 (COVID-19) pandemic continues advancing globally,
reporting of clinical outcomes and risk factors for intensive care unit admission and mortality are …
reporting of clinical outcomes and risk factors for intensive care unit admission and mortality are …
[HTML][HTML] Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis
Background Patients from ethnic minority groups are disproportionately affected by Coronavirus
disease (COVID-19). We performed a systematic review and meta-analysis to explore …
disease (COVID-19). We performed a systematic review and meta-analysis to explore …
[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …
was announced, containing far more mutations in Spike (S) than previously reported …
[HTML][HTML] Ethnic inequalities in COVID-19 infection, hospitalisation, intensive care admission, and death: a global systematic review and meta-analysis of over 200 …
Background COVID-19 has exacerbated existing ethnic inequalities in health. Little is
known about whether inequalities in severe disease and deaths, observed globally among …
known about whether inequalities in severe disease and deaths, observed globally among …
Radiomics signature: a potential biomarker for the prediction of disease-free survival in early-stage (I or II) non—small cell lung cancer
Purpose To develop a radiomics signature to estimate disease-free survival (DFS) in
patients with early-stage (stage I–II) non–small cell lung cancer (NSCLC) and assess its …
patients with early-stage (stage I–II) non–small cell lung cancer (NSCLC) and assess its …
Cellular backpacks for macrophage immunotherapy
Adoptive cell transfers have emerged as a disruptive approach to treat disease in a manner
that is more specific than using small-molecule drugs; however, unlike traditional drugs, cells …
that is more specific than using small-molecule drugs; however, unlike traditional drugs, cells …
[HTML][HTML] Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 …
…, M Pacurar, A Palfreeman, D Pan… - The Lancet Infectious …, 2022 - thelancet.com
Background Some high-income countries have deployed fourth doses of COVID-19 vaccines,
but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We …
but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We …
Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells
Nanoparticulate drug delivery systems are one of the most widely investigated approaches
for developing novel therapies for a variety of diseases. However, rapid clearance and poor …
for developing novel therapies for a variety of diseases. However, rapid clearance and poor …